iShares Global Healthcare ETF
BlackRock (iShares) · Since 2009
Annual fee
0.41%
$41/year per $10,000
Fund size
$1.3B
AUD
Dividend yield
1.65%
Quarterly · approx. as at Q2 2026
Holdings
120
companies
Dividend yield is a trailing distribution figure. Past performance is not a reliable indicator of future returns.
Next estimated distribution: ~September 2026 (estimated, not guaranteed; confirm with the fund manager). Distribution calendar → · View full distribution history →
IXJ provides exposure to global healthcare companies across pharmaceuticals, medical devices, biotechnology and healthcare services. The fund holds a diversified portfolio of international healthcare equities, offering thematic investment in the healthcare sector. With a MER of 0.41% p.a., it tracks a broad global healthcare index. General information only, not financial advice.
Based on publicly available fund data. Not a recommendation to buy or sell.
Strengths
Watch out for
Approximate holdings based on fund category and index. Actual composition may differ.
| Company | Weight |
|---|---|
| UnitedHealth Group Inc. | 5.8% |
| Eli Lilly and Company | 5.2% |
| Johnson and Johnson | 4.6% |
| AbbVie Inc. | 4.1% |
| Merck & Co., Inc. | 3.8% |
| Thermo Fisher Scientific Inc. | 3.2% |
| Abbott Laboratories | 2.9% |
| Danaher Corporation | 2.6% |
| Medtronic PLC | 2.3% |
| Becton Dickinson and Company | 2.1% |
See how IXJ combines with your other ETFs: Stock X-Ray →
| Sector | Weight |
|---|---|
| Financials | 99.9% |
| Cash and/or Derivatives | 0.1% |
| Country | Weight |
|---|---|
| United States | 99.9% |
| Australia | 0.1% |
Historical returns
Past performance is not a reliable indicator of future returns.
Data as at Q2 2026. Past performance is not a reliable indicator of future returns. Figures are approximate total returns in AUD including distributions. Source: fund manager fact sheets.
Compare IXJ with similar ETFs
Side-by-side fees, holdings overlap and performance.
Find near-twins of IXJ →General information only, not financial advice. ETFLens does not hold an AFSL. Always read the relevant PDS and consider seeking advice from a licensed financial adviser.
IXJ provides exposure to global healthcare companies across pharmaceuticals, medical devices, biotechnology and healthcare services.
IXJ's annual management fee is 0.41% p.a. ($41 per $10,000 invested).
IXJ pays distributions quarterly. Distributions are not guaranteed and will vary.